Scarica l'app Stockscreener
1.04
1.96%
0.02
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TPST Giù?
Forum
Previsione
Frazionamento azionario
Tempest Therapeutics Inc Borsa (TPST) Ultime notizie
Tempest Therapeutics files prospectus for sale of 8.9 million shares - scanx.trade
Tempest Therapeutics (NASDAQ: TPST) lines up $50M stock facility that may heavily dilute holders - Stock Titan
Tempest partners Senlang to advance TPST-4003 in China trial - scanx.trade
Form 8K Tempest Therapeutics Inc For: 18 August By Investing.com - Investing.com South Africa
Tempest Therapeutics adjourns special meeting, sets new date for stockholder vote - Investing.com
Tempest Therapeutics Adjourns Special Stockholder Meeting Again - TipRanks
TPST Q1 2026 Earnings: Wider-Than-Expected Losses as Shares Gain 11.33%Balance Sheet Strength - vinanet.vn
Tempest Therapeutics (TPST) Stock Forum and Discussion - Moomoo
TPST Q1 2026 Earnings: EPS Deeply Misses Estimates as No Revenue ReportedPositive Surprise Momentum - Vinanet
TPST Q1 2026 Earnings: Clinical-Stage Biotech Reports Deep EPS Miss as Shares Slide 13.25%EPS Surprise History - vinanet.vn
Tempest Therapeutics Cash Drops to $0.8M Amid Recent Asset Acquisition - Minichart
Tempest Therapeutics Secures Up to $50 Million Equity Facility From Lincoln Park - Minichart
Tempest Therapeutics Cash Drops to $0.8 Million, Raising Going-Concern Risk - Minichart
Form 8K Tempest Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
Tempest Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Tempest Therapeutics Secures Flexible $50 Million Equity Facility - TipRanks
Tempest Therapeutics Q2 loss narrows to $5.2m; advances CAR-T pipeline - scanx.trade
Tempest TherapeuticsEnters $50 Million Common Stock Purchase Agreement With Lincoln Park - TradingView
Tempest Therapeutics (TPST) expands CAR-T pipeline amid $32.9M loss and cash strain - Stock Titan
Tempest Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Tempest Therapeutics Announces Senlang Collaboration to Advance TPST-4003 In Vivo CAR-T Pipeline and Appoints Two New Directors - Quiver Quantitative
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
Tempest Therapeutics (TPST) Surges 13% as Biotech Momentum Builds Above Key SupportAnalyst Downgrade Signals - vinanet.vn
Tempest Therapeutics Inc expected to post a loss of 30 cents a shareEarnings Preview - TradingView
Tempest Therapeutics (TPST) Gains 3% as Biotech Stock Holds Ground Above $0.86 SupportFactor Momentum - vinanet.vn
Tempest Therapeutics (TPST) Slides to $0.86, Testing Support Near $0.82Positive Gamma - dars.gov.et
Tempest Therapeutics (TPST) Shows Modest Uptick, Holding Above Key SupportPrice Target - vinanet.vn
Tempest Therapeutics Inc (TPST) Institutional Confidence - TradingKey
Tempest Therapeutics Adjourns Vote on Governance Changes - TipRanks
Tempest Therapeutics Inc (TPST) Cash Flow - TradingKey
TPST|Tempest Therapeutics Inc|Price:0.942|Chg%:+0.016 - TradingKey
Tempest Therapeutics Inc (TPST) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
Tempest Therapeutics Inc (TPST) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tempest Therapeutics, Inc. Revenue Breakdown – NASDAQ:TPST - TradingView
Tempest Therapeutics Inc (TPST) Valuation: PE, PB & Fair Value Analysis - TradingKey
TPST Q1 2026 Earnings: Wide EPS Miss Highlights Cash Burn ChallengesEarnings Growth Forecast - vinanet.vn
Tempest Therapeutics inks China in vivo CAR-T deal - TipRanks
Tempest Therapeutics, Inc. and Heibei Senlang Biotechnology Co., Ltd. Enter into Product Development and Investigator-Initiated Trial Collaboration Agreement - marketscreener.com
Tempest Therapeutics (TPST) Pulls Back to $0.97, Testing Key SupportSign of Weakness - dars.gov.et
Tempest Therapeutics Announces Strategic Partnership with Senlang to Advance TPST-4003 into First-in-Human Study in Autoimmune Diseases - Quiver Quantitative
Tempest Announces Development Collaboration with Senlang - GlobeNewswire
TPST Q1 2026 Earnings: Wide EPS Miss Highlights Ongoing Clinical-Stage LossesRevenue Per Share - vinanet.vn
Tempest Therapeutics (TPST) Inches Higher Near Resistance as Trading Remains SubduedDeath Cross - vinanet.vn
Tempest Therapeutics (TPST) plans vote on supermajority and written-consent changes - Stock Titan
William Drake Richey Net Worth (2026) - GuruFocus
Tempest advances next-generation in vivo CAR T pipeline - BioWorld News
Tempest Therapeutics (TPST) Slips 3.74% as Stock Tests Key Support ZonePut Call Ratio - vinanet.vn
Tempest plans trial of in vivo CAR-T candidate for autoimmune diseases By Investing.com - Investing.com South Africa
Tempest Therapeutics Announces Advancement of Lead In Vivo CAR-T Candidate TPST-4003 into Planned Autoimmune Disease Trial - Quiver Quantitative
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, - GlobeNewswire
Tempest's planned CAR-T study targets myasthenia gravis and MS - Stock Titan
Tempest Therapeutics (TPST) Stabilizes at $1.0 Support Level After Modest UptickHead and Shoulders - vinanet.vn
Tempest Therapeutics (NASDAQ: TPST) registers 2.43M shares for resale tied to warrants - Stock Titan
[EFFECT] Tempest Therapeutics, Inc. SEC Filing - Stock Titan
Tempest Therapeutics (NASDAQ: TPST) seeks shareholder vote to amend charter - Stock Titan
Tempest Therapeutics (TPST) Edges Lower as Stock Hovers Near Key Support LevelWyckoff Accumulation - po-news-eg.net
Enterprise value to revenue forward of Tempest Therapeutics, Inc. – NASDAQ:TPST - TradingView
TPST Q1 2026 Earnings: Deep EPS Miss as Clinical-Stage Biotech Reports $2.53 Loss Per ShareEarnings Growth Analysis - DonanımHaber
Tempest Therapeutics (TPST) Rallies Modestly as Stock Holds Above Key SupportMomentum ETF - dars.gov.et
Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer - GlobeNewswire
Tempest Therapeutics Registers 2.43 Million Shares for Resale - Moomoo
Form S-3 Tempest Therapeutics Inc For: 26 June By Investing.com - Investing.com Nigeria
1.21%
1.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):